Neoadjuvant and adjuvant treatment of renal cell carcinoma

Kiruthikah Thillai, Suzanne Allan, Thomas Powles, Sarah Rudman, Simon Chowdhury*

*Corresponding author for this work

    Research output: Contribution to journalLiterature reviewpeer-review

    13 Citations (Scopus)

    Abstract

    Locally advanced renal cell cancers have a significant recurrence rate following radical nephrectomy. Traditional cytotoxic chemotherapy and immunotherapy have failed to demonstrate a benefit in the adjuvant setting. Recent advances in the treatment of metastatic renal cell carcinoma using agents that target VEGF and the mTOR pathways have radically changed the way metastatic renal cell carcinoma is treated. These drugs may be able to reduce the rate of recurrence in high-risk disease, and are now being assessed in the neoadjuvant and adjuvant settings. This review summarizes the evidence for targeted treatment in both the neoadjuvant and adjuvant setting, and its use with cytoreductive nephrectomy.

    Original languageEnglish
    Pages (from-to)765-776
    Number of pages12
    JournalEXPERT REVIEW OF ANTICANCER THERAPY
    Volume12
    Issue number6
    DOIs
    Publication statusPublished - Jun 2012

    Keywords

    • adjuvant
    • bevacizumab
    • cytoreductive nephrectomy
    • everolimus
    • neoadjuvant
    • pazopanib
    • renal cell carcinoma
    • sorafenib
    • PHASE-III TRIAL
    • HIGH-DOSE INTERLEUKIN-2
    • POSTOPERATIVE PROGNOSTIC NOMOGRAM
    • FACTOR TARGETED THERAPY
    • ACTIVATED KILLER-CELLS
    • INTERFERON-ALPHA
    • RADICAL NEPHRECTOMY
    • RANDOMIZED-TRIAL
    • CYTOREDUCTIVE NEPHRECTOMY
    • HIGH-RISK

    Fingerprint

    Dive into the research topics of 'Neoadjuvant and adjuvant treatment of renal cell carcinoma'. Together they form a unique fingerprint.

    Cite this